MIRM
Price
$51.92
Change
-$1.36 (-2.55%)
Updated
Jul 15, 04:59 PM (EDT)
Capitalization
2.57B
15 days until earnings call
RARE
Price
$27.20
Change
-$2.03 (-6.94%)
Updated
Jul 15 closing price
Capitalization
2.57B
15 days until earnings call
Interact to see
Advertisement

MIRM vs RARE

Header iconMIRM vs RARE Comparison
Open Charts MIRM vs RAREBanner chart's image
Mirum Pharmaceuticals
Price$51.92
Change-$1.36 (-2.55%)
Volume$4.5K
Capitalization2.57B
Ultragenyx Pharmaceutical
Price$27.20
Change-$2.03 (-6.94%)
Volume$4.77M
Capitalization2.57B
MIRM vs RARE Comparison Chart in %
Loading...
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MIRM vs. RARE commentary
Jul 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIRM is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 16, 2025
Stock price -- (MIRM: $51.98 vs. RARE: $27.20)
Brand notoriety: MIRM and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIRM: 76% vs. RARE: 291%
Market capitalization -- MIRM: $2.57B vs. RARE: $2.57B
MIRM [@Biotechnology] is valued at $2.57B. RARE’s [@Biotechnology] market capitalization is $2.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIRM’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • MIRM’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, MIRM is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIRM’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • MIRM’s TA Score: 5 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MIRM is a better buy in the short-term than RARE.

Price Growth

MIRM (@Biotechnology) experienced а +3.40% price change this week, while RARE (@Biotechnology) price change was -31.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.

Reported Earning Dates

MIRM is expected to report earnings on Nov 12, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($2.58B) and RARE($2.57B) have the same market capitalization . MIRM YTD gains are higher at: 25.707 vs. RARE (-35.346). MIRM has higher annual earnings (EBITDA): -37.56M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. MIRM (278M). RARE has less debt than MIRM: RARE (38.3M) vs MIRM (317M). RARE has higher revenues than MIRM: RARE (591M) vs MIRM (379M).
MIRMRAREMIRM / RARE
Capitalization2.58B2.57B100%
EBITDA-37.56M-449.9M8%
Gain YTD25.707-35.346-73%
P/E RatioN/AN/A-
Revenue379M591M64%
Total Cash278M494M56%
Total Debt317M38.3M828%
FUNDAMENTALS RATINGS
MIRM vs RARE: Fundamental Ratings
MIRM
RARE
OUTLOOK RATING
1..100
7751
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
15100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4290
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (50) in the null industry is in the same range as RARE (50) in the Biotechnology industry. This means that MIRM’s stock grew similarly to RARE’s over the last 12 months.

MIRM's Profit vs Risk Rating (15) in the null industry is significantly better than the same rating for RARE (100) in the Biotechnology industry. This means that MIRM’s stock grew significantly faster than RARE’s over the last 12 months.

MIRM's SMR Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MIRM’s stock grew similarly to RARE’s over the last 12 months.

MIRM's Price Growth Rating (42) in the null industry is somewhat better than the same rating for RARE (90) in the Biotechnology industry. This means that MIRM’s stock grew somewhat faster than RARE’s over the last 12 months.

MIRM's P/E Growth Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MIRM’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MIRMRARE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
75%
Bullish Trend 13 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 1 day ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IGFSX16.33N/A
N/A
VY® Morgan Stanley Global Franchise S2
MEERX8.02N/A
N/A
MassMutual International Eq R3
IEDAX11.78N/A
N/A
Voya Large Cap Value A
TAMVX31.74N/A
N/A
T. Rowe Price Mid-Cap Value Adv
TQCRX19.52N/A
N/A
Touchstone Dividend Equity R6

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with NRIX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
-2.44%
NRIX - MIRM
49%
Loosely correlated
-4.26%
CRNX - MIRM
48%
Loosely correlated
-3.60%
RVMD - MIRM
44%
Loosely correlated
-1.46%
IRON - MIRM
43%
Loosely correlated
-2.55%
KYMR - MIRM
42%
Loosely correlated
+0.02%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-6.94%
MREO - RARE
66%
Closely correlated
-0.58%
IONS - RARE
49%
Loosely correlated
-1.29%
DNLI - RARE
48%
Loosely correlated
-3.54%
SNDX - RARE
47%
Loosely correlated
-6.50%
VCYT - RARE
46%
Loosely correlated
-5.29%
More